Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company plc    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Perrigo plans to separate prescription pharma business

share with twitter share with LinkedIn share with facebook
share via e-mail
08/09/2018 | 10:35am EST
FILE PHOTO: Birds are seen on the logo of generic drugmaker Perrigo Co outside their new factory in the city of Yeruham

(Reuters) - Perrigo Co Plc said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker's shares down about 8 percent.

Generic drugmakers such as Perrigo, Mylan and Teva Pharmaceutical Industries have suffered over the past few years as price erosion has pressured their bottom lines.

"The company (Perrigo) has been actively discussing this potential separation for some time and the lack of a buyer thus far to us suggests this won't be easy," RBC Capital Markets analyst Randall Stanicky said.

"We do not think it is understood how dilutive this is likely to be."

Perrigo's announcement comes just a day after larger rival Mylan said it was evaluating all strategic options, citing a tough U.S. environment for generic drugmakers.

Perrigo said the separation is expected to be completed in the second half of 2019 and the board would explore all options, including a possible tax-efficient separation to shareholders, a sale or merger.

Analysts said the plan to separate the prescription pharmaceuticals business was "long overdue".

Regulatory, supply chain and competitive headwinds have taken a toll on a differentiated business that is very niche and highly profitable, Berenberg analyst Patrick Trucchio said.

Perrigo on Thursday also missed second-quarter revenue and profit estimates and cut its full-year forecasts, largely due to lower sales in the prescription drugs business, which accounted for nearly a fifth of over sales of $1.19 billion.

The company's prescription business serves patients and hospitals with topical medicines at affordable rates, while the consumer health division makes products such as vitamins, cough and cold medicines and personal care products.

Shares of the company, which has engaged Barclays as its financial adviser, were down at $72.36 on Thursday.

Up to Wednesday's close, shares had fallen about 10 percent since the start of the year, compared with an 8.9 percent jump for the S&P500 healthcare index <.SPXHC>.

(Reporting by Tamara Mathias and Ishita Chigilli Palli in Bengaluru; Editing by Gopakumar Warrier and Sriraj Kalluvila)

By Tamara Mathias

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -4.42% 25766.64 Delayed Quote.-5.54%
MYLAN N.V. -4.40% 18.68 Delayed Quote.-7.06%
NASDAQ 100 -4.93% 8436.666084 Delayed Quote.1.17%
NASDAQ COMP. -4.61% 8566.479823 Delayed Quote.-0.08%
PERRIGO COMPANY PLC -14.27% 51.82 Delayed Quote.17.44%
S&P 500 -4.42% 2978.76 Delayed Quote.-3.54%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PERRIGO COMPANY PLC
02/27PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
02/27PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
02/27PERRIGO : 4Q Earnings Snapshot
AQ
02/27PERRIGO COMPANY PLC : Ex-dividend day for
FA
02/26PERRIGO : and Catalent Announce FDA Approval of Perrigo's AB-Rated Generic Versi..
AQ
02/25PERRIGO : Thinking about trading options or stock in Enphase Energy, Home Depot,..
PR
01/14PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
01/07PERRIGO : Advances Consumer Self-Care Growth Strategy with Ranir Subsidiary Acqu..
AQ
2019PERRIGO : Donates a Total of $75,000 to Wings of Hope Hospice and Wings Home
AQ
2019PERRIGO : Announces Closing of Prevacid24HR Acquisition, Advancing Consumer Self..
AQ
More news
Financials (USD)
Sales 2020 5 111 M
EBIT 2020 843 M
Net income 2020 549 M
Debt 2020 2 409 M
Yield 2020 1,67%
P/E ratio 2020 12,9x
P/E ratio 2021 16,2x
EV / Sales2020 1,85x
EV / Sales2021 1,79x
Capitalization 7 053 M
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 58,58  $
Last Close Price 51,82  $
Spread / Highest target 35,1%
Spread / Average Target 13,1%
Spread / Lowest Target 2,28%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Raymond P. Silcock Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC17.44%7 053
JOHNSON & JOHNSON-0.84%378 557
ROCHE HOLDING AG5.13%287 870
MERCK AND COMPANY-12.11%203 526
NOVARTIS-5.57%200 481
PFIZER, INC.-13.40%192 145